摘要
目的检测骨髓增生异常综合征(MDS)患者血清白细胞介素-32(IL-32)及白细胞介素-18(IL-18)水平变化,探讨两指标与MDS发生、发展及预后的相关性。方法应用酶联免疫吸附试验(ELISA)分别测定16例确诊为MDS患者化疗前后IL-32、IL-18的表达情况,并与20例健康体检者作对照。结果 IL-32在MDS患者血清中的表达水平为(83.94±10.43)ng/L,显著高于正常对照组(45.91±11.48)ng/L;IL-18在MDS患者血清中的表达水平为(159.62±20.86)ng/L,显著高于正常对照组(101.17±19.99)ng/L。IL-32和IL-18的表达水平与正常对照组比较,差异具有统计学意义(P均<0.05)。结论 IL-32和IL-18与MDS的发病及发展密切相关。检测MDS患者IL-32和IL-18表达水平变化,有助于临床对病情转归的判断。
Objective：The serum interleukin-32（IL-32） and interleukin-18（IL-18） level changes were detected in Myelodysplastic syndrome（MDS） patients,explore the two indicators correlation with MDS occurrence,development and prognosis.Methods：IL-32,IL-18 expression levels were measured by Enzyme-linked immunosorbent assay（ELISA） in 16 patients diagnosed MDS patients,and 20 healthy controls.Results：The serum IL-32 expression level of patients with MDS（83.94 ± 10.43） ng/L,significantly higher than the control group（45.91 ± 11.48） ng/L;the serum IL-18 expression leve of patients with MDS（159.62 ± 20.86） ng/L,significantly higher than the control group（101.17 ± 19.99） ng/L.The expression levels of IL-32 and IL-18 compared with the normal control group,the difference was statistically significant（P 0.05）.Conclusion：IL-32 and IL-18 are closely related to MDS incidence and development.Detect the IL-32 and IL-18 expression levels changes in MDS patients,contribute to the clinical judgment of disease outcome.
出处
《泰山医学院学报》
CAS
2013年第1期1-2,共2页
Journal of Taishan Medical College
基金
山东省自然科学基金项目(2012ZRB14170)
泰安市科技局计划项目(2011D2039)
泰山医学院大学生课题(201101044)
